

ACCELERATED DOCUMENT DISTRIBUTION SYSTEM

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 9304260182 DOC. DATE: 93/04/20 NOTARIZED: NO DOCKET #
 FACIL: 50-269 Oconee Nuclear Station, Unit 1, Duke Power Co. 05000269
 50-270 Oconee Nuclear Station, Unit 2, Duke Power Co. 05000270
 50-287 Oconee Nuclear Station, Unit 3, Duke Power Co. 05000287
 50-369 William B. McGuire Nuclear Station, Unit 1, Duke Power Co. 05000369
 50-370 William B. McGuire Nuclear Station, Unit 2, Duke Power Co. 05000370
 50-413 Catawba Nuclear Station, Unit 1, Duke Power Co. 05000413
 50-414 Catawba Nuclear Station, Unit 2, Duke Power Co. 05000414

AUTH. NAME AUTHOR AFFILIATION
 TUCKER, H.B. Duke Power Co.
 RECIP. NAME RECIPIENT AFFILIATION
 Document Control Branch (Document Control Desk)

SUBJECT: Forwards fitness-for-duty program unsatisfactory performance test result, per 10CFR26, App A.

DISTRIBUTION CODE: A022D COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 5
 TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES: ASLB 1cy. 05000413
 ASLB 1cy. 05000414

	RECIPIENT		COPIES		RECIPIENT	COPIES	
	ID CODE/NAME		LTTR	ENCL		ID CODE/NAME	LTTR
	PD2-3 PD		1	1	WIENS, L	1	1
	REED, T		1	1	MARTIN, R	1	1
INTERNAL:	ACRS		1	1	NRR/DRSS/PSGB	1	1
	NUDOCS-ABSTRACT		1	1	REG FILE 01	1	1
	RGN2 . 02		1	1			
EXTERNAL:	NRC PDR		1	1	NSIC	1	1
NOTES:			1	1			

NOTE TO ALL "RIDS" RECIPIENTS:

PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK, ROOM P1-37 (EXT. 504-2065) TO ELIMINATE YOUR NAME FROM DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR 12 ENCL 12

MPA-4

Duke Power Company
P.O. Box 1006
Charlotte, NC 28201-1006

HAL B. TUCKER
Senior Vice President
Nuclear Generation
(704)382-4531



DUKE POWER

April 20, 1993

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, D. C. 20555

Subject: Fitness-For-Duty Program
Unsatisfactory Performance Test Result

Oconee Nuclear Station
Docket Numbers 50-269, -270 and -287
McGuire Nuclear Station
Docket Numbers 50-369 and -370
Catawba Nuclear Station
Docket Numbers 50-413 and -414

Attached is a report, as required by 10CFR 26, Appendix A, of an unsatisfactory performance test result.

If there are any questions, please contact G. A. Copp at (704) 382-5826.

H. B. Tucker
Senior Vice President

xc: Mr. Victor Nerses, Project Manager
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Mail Stop 14H25, OWFN
Washington. D. C. 20555

9304260182 930420
PDR ADOCK 05000269
P PDR

Printed on recycled paper

A022
11

U. S. Nuclear Regulatory Commission
April 20, 1993
Page 2

Mr. R. E. Martin, Project Manager
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Mail Stop 14H25, OWFN
Washington, D. C. 20555

Mr. L. A. Wiens, Project Manager
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Washington, D. C. 20555

Mr. S. D. Ebnetter, Regional Administrator
U. S. Nuclear Regulatory Commission - Region II
101 Marietta Street, NW - Suite 2900
Atlanta, GA 30323

Duke Power Company
Health & Safety Division
P.O. Box 1006
Charlotte, NC 28201-1006



DUKE POWER

April 19, 1993

SUBJECT: False Negative Blind urine Drug Screen

On February 18, 1993 a blind spiked specimen, Req. #4699273, ID #311861075, with amphetamine was submitted from McGuire Nuclear Station to SmithKline Beecham Laboratory in Atlanta, Georgia. The result was negative. Dr. Jerry McHan, Toxicologist, of Quality Assurance Associates investigated the result through the laboratory. The laboratory's written reply was delayed to him. However, a satisfactory explanation letter (see attached) was sent to him dated April 5, 1993 and he forwarded the letter to me. This is a reasonable explanation for this false negative result.

W. E. Dukes, Jr., MD

W. E. Dukes, Jr., MD
Corporate Medical Director
Duke Power Company

SB
SmithKline Beecham
Clinical Laboratories

April 5, 1993

Dr. Jerry McHan
1327 Fairview Road, NE
Atlanta, GA 30306


Subject: Duke Power Blind Sample 311861075

Dear Dr. McHan,

On March 11, 1993, you requested that the data on the above specimen be reviewed and that the specimen be reanalyzed. At that time, you indicated that this was a blind sample and that you expected a positive result for amphetamine. A review of the data indicated that the sample screened positive for amphetamines using the EMIT Immunoassay. On the secondary screening method (FPIA) for amphetamines, it was negative. At that point no further testing occurred and the specimen was reported "negative" for amphetamines. We were unable to reanalyze the specimen since it had been discarded. It is our laboratory's policy to discard negative specimens seven days after receipt, and this specimen was received on February 19, 1993.

I understand that the above information was previously provided to you over the phone by Ben Wells. This letter is to confirm and follow up on that conversation. If I can be of any further assistance to you in this matter, please contact me.

Sincerely,



R. H. Barry Sample, Ph.D.
Director of Forensic Toxicology
SmithKline Beecham Clinical Laboratories

U. S. Nuclear Regulatory Commission
April 20, 1993
Page 3

bxc: W. E. Dukes, Jr. M.D.
Iris Crawford
GS-801.01